Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLYCD | O95822 | 4/20 | 0.57 |
| ▸ | EGFR | P00533 | 2/20 | 0.54 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 4/20 | 0.47 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.47 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2678371 | 0.89 | EGFR (0.56) | MLYCDEGFRERBB2TP53HPGD | |
| SCHEMBL21224537 | 0.86 | EGFR (0.50) | MLYCDEGFRERBB2HPGDALDH1A1 | |
| SCHEMBL21224990 | 0.86 | EGFR (0.50) | MLYCDEGFRERBB2HPGDALDH1A1 | |
| SCHEMBL21224557 | 0.86 | EGFR (0.50) | MLYCDEGFRERBB2HPGDALDH1A1 | |
| SCHEMBL9694832 | 0.86 | MLYCD (0.72) | MLYCDEGFRERBB2TP53HPGD | |
| SCHEMBL467330 | 0.84 | HPGD (0.56) | MLYCDHPGDALDH1A1NPC1L3MBTL1 | |
| SCHEMBL1003735 | 0.80 | TP53 (0.68) | MLYCDEGFRERBB2TP53HPGD | |
| SCHEMBL11485018 | 0.80 | HPGD (0.56) | MLYCDEGFRERBB2HPGDALDH1A1 | |
| SCHEMBL15475072 | 0.79 | TP53 (0.51) | MLYCDEGFRERBB2TP53HPGD | |
| SCHEMBL2224812 | 0.79 | MLYCD (0.37) | MLYCDEGFRERBB2TP53HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 479 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0830349-B1 | METHOD FOR PREPARING N, N'-DISUBSTITUED CYCLIC UREAS | DU PONT PHARM CO (US) | 2000-03-22 | — | — | EP | claimed |
| US-5877312-A | Method for preparing alkylating agents for their use for alkylating cyclic ureas | DUPONT PHARMACEUTICALS COMPANY (US) | 1999-03-02 | — | — | US | claimed |
| US-5637780-A | Method for preparing alkylating agents and their use for alkylating cyclic ureas | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-06-10 | — | — | US | claimed |
| US-10961405-B2 | Fluorine-containing acetophenone derivative, fluroine based additive, curable composition including same, and cured product thereof | DIC CORPORATION (JP) | 2021-03-30 | — | — | US | disclosed |
| EP-1657286-B1 | Radiation curable ink jet ink, comprising a polymerisation initiation sensitising dye | FUJIFILM CORP (JP) | 2018-07-04 | — | — | EP | disclosed |
| US-9957402-B2 | Compound, active energy ray curable composition, cured article thereof, printing ink, and inkjet recording ink | DIC CORPORATION (JP) | 2018-05-01 | — | — | US | disclosed |
| EP-1859954-B2 | Planographic printing plate precursor and stack thereof | FUJIFILM CORP (JP) | 2017-11-08 | — | — | EP | disclosed |
| EP-2042921-B1 | Pigment dispersion composition, photocurable composition and color filter | FUJIFILM CORP (JP) | 2017-10-25 | — | — | EP | disclosed |
| EP-2006738-B1 | Lithographic printing plate precursor | FUJIFILM CORP (JP) | 2017-09-06 | — | — | EP | disclosed |
| EP-1975707-B1 | Curable composition and planographic printing plate precursor | FUJIFILM CORP (JP) | 2017-07-19 | — | — | EP | disclosed |
| US-20170152391-A1 | COMPOUND, ACTIVE ENERGY RAY CURABLE COMPOSITION, CURED ARTICLE THEREOF, PRINTING INK, AND INKJET RECORDING INK | DIC CORPORATION (JP) | 2017-06-01 | — | — | US | disclosed |
| EP-0822447-A1 | Photopolymerizable composition | FUJI PHOTO FILM CO., LTD. (JP) | 1998-02-04 | — | — | EP | disclosed |
| US-5703140-A | CONTAINS ETHYLENICALLY UNSATURATED BOND, OXIME ETHER COMPOUND, SPECTRAL SENSITIZING DYE | FUJI PHOTO FILM CO., LTD. (JP) | 1997-12-30 | — | — | US | disclosed |
| US-5637780-A | Method for preparing alkylating agents and their use for alkylating cyclic ureas | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-06-10 | — | — | US | disclosed |
| US-5609992-A | UNSATURATED COMPOUND AND A THIAZOLONE PHOTOSENSITIZER | FUJI PHOTO FILM CO., LTD. (JP) | 1997-03-11 | — | — | US | disclosed |
| EP-0726497-A2 | Photopolymerizable composition | FUJI PHOTO FILM CO., LTD. (JP) | 1996-08-14 | — | — | EP | disclosed |
| EP-0726498-A1 | Photopolymerizable composition | FUJI PHOTO FILM CO., LTD. (JP) | 1996-08-14 | — | — | EP | disclosed |
| EP-0724197-A1 | Photopolymerizable composition | FUJI PHOTO FILM CO., LTD. (JP) | 1996-07-31 | — | — | EP | disclosed |
| US-5532356-A | Method for preparing N,N'-disubstituted cyclic ureas | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-07-02 | — | — | US | disclosed |
| EP-0710887-A1 | Photopolymerizable composition | FUJI PHOTO FILM CO., LTD. (JP) | 1996-05-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170152391-A1 | COMPOUND, ACTIVE ENERGY RAY CURABLE COMPOSITION, CURED ARTICLE THEREOF, PRINTING INK, AND INKJET RECORDING INK | CCNT1, EIF4A1, MARK1 | MLYCD 4485/4885EGFR 3247/4885ERBB2 2388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.